Moreover, PIK3CA altered tumours that have been rendered resistant to PI3Kα inhibition through loss of PTEN show lack of FOXM1 downregulation, suggesting FOXM1 may play a role in limiting the efficacy of agents targeting the PI3K-AKT pathway. The gene discussed is AKT1; the disease is neoplasm.